These clinical trials involve cancer vaccines [such as, dendritic cell (DC) vaccine, melanoma-associated antigen 3 (MAGE-3) peptide vaccine], adoptive cell therapies [such as cytokine-induced killer (CIK) cells, DC-CIK, chimeric antigen receptor (CAR)-T cell therapy], and immune checkpoint inhibitor (ICI) therapies. The gene discussed is MAGEA3; the disease is cancer.